TICKERNERD
Menu
HAEHAEHealthcare · Medical Devices

HAE Stock Forecast: Haemonetics Corp. Price Predictions for 2026-2027

Last close, 21 Aug 2026
$109
+0.54% on the day

The 11 Wall Street analysts covering Haemonetics Corp. hold a median 12-month price target of $108 — -1.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 98 of 100 as at 22 Aug 2026 — among the strongest tenth. The factors read stronger than the Street's target implies. That gap is the story on this page.

Market cap
$5.0B
Ticker Nerd rank
98 / 100
Median analyst target
$108
Analysts covering
11
Total return, dividends reinvested
1W
+19.8%
1M
+39.4%
YTD
+35.7%
1Y
+101.6%
From 52W high
0.0%
From 52W low
+128.2%
$48
$109
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

HAE stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Haemonetics Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
98 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Issuance
97
Volatility
93
Accruals
92
Value
87
Revisions
86
Quality
85
Momentum
71
Growth
46
Size
24

Issuance (97): The share count has been shrinking and the company is not leaning on new borrowing.

Growth (46): Sales and profits are flat, shrinking, or growing more slowly than they were.

Size (24): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

HAE stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on HAE, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$40$60$80$100$120Oct 25Jan 26Apr 26Jul 26HAEHigh $120Median $108Low $86

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says11 analysts
8 Buy3 Hold0 Sell
Low $86Median $108High $120

The green dot is the last close — the median target sits −1.2% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 7 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
21 Aug 2026BairdMaintainsOutperform$96 → $119
19 Aug 2026Barrington ResearchMaintainsOutperform$95 → $118
18 Aug 2026BTIGMaintainsBuy$96 → $110
7 Aug 2026CitigroupMaintainsNeutral—
7 Aug 2026CitigroupMaintainsNeutral$79 → $92
7 Aug 2026JP MorganMaintainsNeutral$62 → $86
7 Aug 2026JP MorganMaintainsNeutral—
6 Aug 2026BTIGMaintainsBuy$84 → $96
6 Aug 2026BTIGMaintainsBuy—
15 July 2026MizuhoMaintainsOutperform$85 → $90
15 July 2026MizuhoMaintainsOutperform—
26 June 2026BTIGReiteratesBuy$84
26 June 2026BTIGReiteratesBuy—
17 June 2026BTIGReiteratesBuy—
15 June 2026MizuhoMaintainsOutperform—
28 May 2026CitigroupMaintainsNeutral—
22 May 2026B of A SecuritiesUpgradeBuy—
12 May 2026Barrington ResearchMaintainsOutperform—
8 May 2026JP MorganMaintainsNeutral—
13 Apr 2026MizuhoMaintainsOutperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. HAE appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

HAE analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
+1.5%
Analysts raising
9
Analysts cutting
0
Fundamentals

Haemonetics Corp. (HAE) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
52.6×

Cheaper than 14% of US stocks

Price / sales
3.7×

Cheaper than 35% of US stocks

Price / book
5.9×

Cheaper than 19% of US stocks

EV / EBITDA
16.4×

Cheaper than 21% of US stocks

Growth & margins
Revenue growth (YoY)
5.6%

Higher than 40% of US stocks

Earnings growth (YoY)
−3.0%

Higher than 33% of US stocks

Gross margin
59.8%

Higher than 73% of US stocks

Operating margin
17.9%

Higher than 76% of US stocks

Net margin
7.1%

Higher than 64% of US stocks

Returns & dividend
Return on equity
11.2%

Higher than 66% of US stocks

Return on assets
6.6%

Higher than 83% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

HAE vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
HAEHaemonetics Corp.$5.0B
98
ITGRInteger Holdings Corp.$4.4B
72
LIVNLivaNova PLC$4.3B
98
IRTCiRhythm Holdings, Inc.$4.2B
78
TMDXTransMedics Group, Inc.$3.3B
29
BRKRBruker Corp.$9.1B
84
AXGNAxoGen, Inc.$2.7B
77

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Haemonetics Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest HAE news & analysis

Haemonetics: Worth Speculating On This Recurring Medtech Plasma Model

Seeking Alpha · 21 Aug 2026positive

The article describes Haemonetics as a medtech company increasingly generating recurring revenues from plasma consumables, supported by its higher-margin MedSurg segment, which together provide a durable growth profile. It notes that a recent agreement with CSL could expand this potential.

Why it matters — HAE watchers would care because the piece highlights the company's shift toward recurring plasma revenue and a new CSL agreement that could broaden its growth prospects.

Here's Why Haemonetics (HAE) is a Strong Momentum Stock

Zacks Investment Research · 18 Aug 2026positive

Zacks Investment Research highlights Haemonetics (HAE) as a strong momentum stock, pointing to its Style Scores as a tool for identifying market-beating stocks for investment portfolios.

Why it matters — The piece signals that HAE is being recognized for favorable momentum characteristics, which may be of interest to investors tracking the stock's performance.

Haemonetics (HAE) is a Top-Ranked Value Stock: Should You Buy?

Zacks Investment Research · 17 Aug 2026positive

Zacks Investment Research highlighted Haemonetics (HAE) as a top-ranked value stock using its Style Scores system, which helps investors identify stocks based on their investing style. The piece promotes the tool as a way to easily find top-rated stocks.

Why it matters — This matters to Haemonetics watchers because it signals that the company is being recognized by a stock-rating service for its value characteristics, which may draw investor attention.

HAE Stock Gains on Q1 Earnings & Revenue Beat, Fiscal '27 View Up

Zacks Investment Research · 14 Aug 2026positive

Haemonetics reported Q1 earnings and revenue that beat expectations, prompting the company to raise its fiscal 2027 revenue guidance. The results were supported by growth in the Plasma segment and stronger cash generation.

Why it matters — A guidance raise following a beat on both earnings and revenue signals improving operational momentum, making this a key data point for investors tracking Haemonetics' financial trajectory.

Haemonetics (HAE) Reliance on International Sales: What Investors Need to Know

Zacks Investment Research · 11 Aug 2026neutral

Zacks examines Haemonetics' reliance on international sales and what its international revenue patterns may imply for Wall Street forecasts and the company's prospective stock trajectory.

Why it matters — A HAE watcher would care because the company's international revenue exposure can influence analyst forecasts and the outlook for the stock.

FAQ

Frequently asked questions about HAE stock

What is the HAE stock price forecast for 2026-2027?

The 11 Wall Street analysts covering Haemonetics Corp. have a median 12-month price target of $108, with estimates ranging from $86 to $120. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is HAE stock a buy right now?

Of the 11 analysts covering Haemonetics Corp., 8 rate it a Buy, 3 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Haemonetics Corp. 98 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank HAE?

As at 22 Aug 2026, Haemonetics Corp. ranks 98 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Issuance (97 of 100).

Will HAE stock go up?

No one can know that. What the data says: the median 12-month target from 11 analysts implies -1.2% from the last close, and Ticker Nerd's factor model ranks Haemonetics Corp. 98 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the HAE stock forecast for 2030?

No analyst covering Haemonetics Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for HAE are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $86 to $120 over the next 12 months.

How has HAE stock performed over the past year?

Haemonetics Corp. returned +101.6% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Haemonetics Corp. do?

Haemonetics Corporation is a global healthcare company dedicated to providing innovative blood management solutions for organizations around the world. The company plays a crucial role in the healthcare industry by offering devices and services that aim to improve the quality, efficiency, and safety of blood supply.

What is the latest news on HAE?

The most recent item we track (Seeking Alpha, 21 Aug 2026): "Haemonetics: Worth Speculating On This Recurring Medtech Plasma Model". The article describes Haemonetics as a medtech company increasingly generating recurring revenues from plasma consumables, supported by its higher-margin MedSurg segment, which together provide a durable growth profile. It notes that a recent agreement with CSL could expand this potential.

Company

About Haemonetics Corp.

Haemonetics Corporation is a global healthcare company dedicated to providing innovative blood management solutions for organizations around the world. The company plays a crucial role in the healthcare industry by offering devices and services that aim to improve the quality, efficiency, and safety of blood supply. Haemonetics is known for its comprehensive portfolio, which includes blood collection and processing systems, plasma collection devices, and software solutions for blood centers and hospitals. The core focus of Haemonetics' offerings lies in enhancing blood donor and patient care, optimizing blood banks' operations, and ensuring the safety and availability of blood and blood components. It serves a wide array of sectors, including hospitals, blood centers, and plasma collection centers, facilitating the global demand for transfusion medicine. With its headquarters in Boston, Massachusetts, Haemonetics continues to influence the landscape of healthcare through its commitment to innovation and its significant contributions to enhancing blood management practices. By catering to a vital segment of the healthcare system, Haemonetics Corporation supports the delivery of essential medical treatments and therapies worldwide.

CEO Mr. Christopher A. Simon · 3,009 employees · United States · https://www.haemonetics.com